Increasing Wellbutrin Dosage from 150 to 300 mg: What to Expect
Author:
Blossom Editorial
Mar 13, 2026
If you’ve been taking Wellbutrin (bupropion) at 150 mg and your provider has recommended increasing to 300 mg, you’re not alone; this is one of the most common and routine dose adjustments made with this medication.
In fact, 300 mg is the typical target dose for treating major depressive disorder with two formulations of Wellbutrin: Wellbutrin XL (extended-release) and Wellbutrin SR (sustained-release). Many providers start patients at 150 mg for a few days to a week before increasing the dosage. The gradual approach helps your body adjust and reduces the likelihood of adverse events such as seizures.
Here’s what to know about why your dose might be going up, what to expect during the transition, and how to manage any temporary side effects while you adjust.
Key Takeaways
The standard target dose for Wellbutrin XL is 300 mg once daily for depression. Starting at 150 mg for the first four to seven days helps reduce the risk of side effects and lowers the risk of dose-related adverse events such as seizures.
The dose increase from 150 mg to 300 mg may cause temporary side effects like headache, insomnia, dry mouth, or restlessness, which typically improve within two to three weeks as your body adjusts to the higher dose.
Full antidepressant effects at the 300 mg dose may take four to six weeks to become fully apparent. Stay in regular contact with your provider during this transition to monitor your response and make any needed adjustments.
Why Your Provider is Increasing Your Dose
According to the FDA, the recommended starting dose for Wellbutrin XL for major depressive disorder is 150 mg once daily in the morning, with an increase to the 300 mg target dose after four days. For seasonal affective disorder, the timeline is slightly longer — providers may wait one week before increasing.
Common reasons your provider may increase your dose include:
Standard titration: For many patients, the increase to 300 mg is part of the planned treatment protocol, not a response to inadequate improvement. It’s simply how the medication is designed to be prescribed.
Insufficient symptom relief: If you’ve been at 150 mg for several weeks and your symptoms haven’t improved enough, 300 mg may provide the additional therapeutic effect needed.
Good tolerability: If you’ve tolerated 150 mg well without bothersome side effects, your provider can confidently increase to the therapeutic target dose.
Switching antidepressants: If your provider recommends switching from antidepressants such as SSRIs or SNRIs due to intolerable side effects, they may initiate a starting dose of Wellbutrin XL at 150 mg and gradually taper the first medication off before increasing the dose of Wellbutrin XL to full therapeutic strength.
Note: Any dosage-related information provided about Wellbutrin is intended for general educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.
How Wellbutrin Works at Different Doses
Wellbutrin is a norepinephrine-dopamine reuptake inhibitor (NDRI). Unlike SSRIs and SNRIs, it does not significantly affect serotonin. Instead, it increases the availability of dopamine and norepinephrine in the brain, neurotransmitters closely tied to motivation, energy, focus, and pleasure. This unique mechanism explains why Wellbutrin has a different side effect profile than most other antidepressants, particularly regarding weight and sexual function.
Wellbutrin XL works by inhibiting dopamine and norepinephrine transporters, which reduces the reuptake of dopamine and norepinephrine into the nerve cells. This increases the levels of these neurotransmitters in the brain, where they are able to produce desired effects. However, the exact mechanism of its antidepressant effect is not fully understood.
At 300 mg, Wellbutrin XL produces greater inhibition of dopamine and norepinephrine reuptake than at 150 mg, which can translate to more robust improvements in mood, energy, motivation, and concentration. A clinical trial directly comparing 150 mg and 300 mg doses of Wellbutrin SR found that both were more effective than placebo for treating depression.
In some cases, if no clinical improvement is observed after four weeks at 300 mg, the dosage may be increased to the maximum of 450 mg daily.
A long-term relapse prevention study demonstrated that patients who maintained treatment with bupropion SR (a generic version of Wellbutrin SR) at 300 mg daily had significantly lower relapse rates compared to those switched to placebo. The median time to relapse was greater than 44 weeks for the bupropion group compared to 24 weeks for placebo.
What to Expect During the Transition from 150 to 300 mg
Timeline for Side Effects and Improvement
As your body adjusts to the higher dose, you may notice some temporary changes. Here’s a general timeline of what to expect when taking Wellbutrin:
Days 1–7 (Week 1): Side effects are typically most noticeable during the first week at the new dose. You may experience headache, dry mouth, insomnia, mild nausea, increased energy, or feeling jittery or restless. These effects are common during dose adjustments and often improve as the body adapts to the medication.
Weeks 2–3: Most initial side effects begin to diminish as your body adapts to the new dose level. Sleep often returns to normal, and the “wired” or restless feeling typically fades.
Weeks 4–6: This is when the full therapeutic benefits of the 300 mg dose usually become apparent. Energy, motivation, concentration, and overall mood often show the most meaningful improvement during this window.
Common Side Effects at 300 mg
Wellbutrin XL has a similar bioavailability to Wellbutrin SR. Placebo-controlled clinical trials with the sustained-release formulation yield data on side effects, which extend to the extended-release formulation. The most frequently reported side effects at the 300 mg dose of Wellbutrin SR include:
Headache (most commonly reported at 26%)
Dry mouth (reported in about 17% of patients)
Insomnia or difficulty falling asleep (11%)
Nausea (usually mild and temporary; 13%)
Dizziness
Agitation, restlessness, or feeling “wired”
Constipation
Increased sweating
Tremor
Rash
Importantly, Wellbutrin is one of the few antidepressants that is less commonly associated with weight gain or sexual dysfunction, two of the most commonly reported and distressing side effects of SSRIs and SNRIs. In clinical studies, patients taking Wellbutrin actually experienced slight weight loss at both the 150 mg and 300 mg dose levels. However, some individuals may experience these side effects.
Important Safety Considerations
Seizure risk: The risk of seizures with Wellbutrin is dose-related. At 300 mg daily, the risk remains low (approximately 0.1% for the sustained release variant), but it increases significantly at doses above 450 mg daily (0.4%). Wellbutrin is contraindicated in people with seizure disorders, active eating disorders (anorexia or bulimia), and those undergoing abrupt discontinuation of alcohol, sedatives, or antiepileptic drugs.
Drug interactions: Wellbutrin is known to interact with several drugs, including other antidepressants, MAOIs, stimulants, beta blockers, antipsychotic drugs, and antiepileptic drugs. The adverse effects caused by the interaction can vary. For instance, interaction with MAOIs can cause high blood pressure, while interaction with stimulants can increase the risk of seizures. It’s important to share your medical history with your provider so they can determine if Wellbutrin is right for you and what dose may be appropriate.
Take it in the morning: To minimize insomnia, take Wellbutrin XL in the morning. Avoid taking it too late in the day, as its activating properties can interfere with sleep.
Don’t crush or split XL tablets: Extended-release tablets must be swallowed whole. Crushing, splitting, or chewing them releases the entire dose at once, which can increase the risk of seizures and other side effects.
Limit alcohol: People who drink alcohol heavily or who stop drinking abruptly should discuss alcohol use with their clinician, as alcohol can increase the risk of seizures when taking Wellbutrin.
Caffeine awareness: Some people find that caffeine increases jitteriness, anxiety, or insomnia when combined with the stimulating effects of Wellbutrin, especially during the dose adjustment period. Consider reducing caffeine intake temporarily if you notice these effects. Caffeine is present in certain foods, drinks, supplements, and even some medications.
When 300 mg of Wellbutrin May Not Be Enough
If you’ve been at 300 mg for at least four to six weeks without adequate improvement in your symptoms, your provider has several options to consider:
Increasing to 450 mg daily: This is the maximum recommended dose. Wellbutrin XL is available in strengths of 150 mg and 300 mg. Forfivo XL is another brand of bupropion available as a 450 mg pill. The seizure risk does increase at this dose, so close monitoring is important.
Adding another medication: Wellbutrin is commonly used as an augmentation strategy — added to an SSRI or SNRI to boost its antidepressant effect. This combination can be effective for treatment-resistant depression.
Switching medications: If Wellbutrin at an adequate dose hasn’t been helpful, a different class of antidepressant may be more effective for your specific depression subtype.
Your Treatment Journey with Blossom Health
At Blossom Health, our providers work with you to personalize treatment — they’ll tailor your dose to your unique needs and combine medication with therapy to understand which treatment plan best integrates with your life.
We’re here to guide you every step of the way so you feel supported and confident in your care. Get started today.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. The information provided should not replace consultation with a qualified healthcare provider. Individual responses to medications can vary significantly, and what applies to one person may not be safe for another. Always consult with your doctor or pharmacist before making any decisions about medication changes, discontinuation, or interactions with other substances.
If you’re experiencing concerning symptoms or side effects, please seek professional help from a healthcare provider. In case of a medical emergency, contact your local emergency services immediately or call 911. For mental health emergencies, contact the National Suicide Prevention Lifeline at 988.
Sources
U.S. Food and Drug Administration. (2025). Wellbutrin XL (bupropion hydrochloride extended-release) tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021515s049lbl.pdf
U.S. Food and Drug Administration. (2025). Wellbutrin SR (bupropion hydrochloride) sustained-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020358s070lbl.pdf
Reimherr, F. W., Cunningham, L. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998). A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clinical therapeutics, 20(3), 505–516. https://doi.org/10.1016/s0149-2918(98)80060-x
Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2024 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/
Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005). 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Primary care companion to the Journal of clinical psychiatry, 7(3), 106–113. https://pmc.ncbi.nlm.nih.gov/articles/PMC1163271/
Stahl, S. M., Pradko, J. F., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004). A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Primary care companion to the Journal of clinical psychiatry, 6(4), 159–166. https://pmc.ncbi.nlm.nih.gov/articles/PMC514842
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M., & Metz, A. (2002). Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biological psychiatry, 51(9), 753–761. https://pubmed.ncbi.nlm.nih.gov/11983189/
Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic advances in psychopharmacology, 6(2), 99–144. https://pmc.ncbi.nlm.nih.gov/articles/PMC4837968/
National Institute of Mental Health. (2023, December). Mental health medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
Cleveland Clinic. (n.d.). Bupropion extended‑release tablets: Drug information. https://my.clevelandclinic.org/health/drugs/19412-bupropion-extended-release-tablets-depressionmood-disorders
Mayo Clinic. (2026). Bupropion (oral route): Proper use. https://www.mayoclinic.org/drugs-supplements/bupropion-oral-route/proper-use/drg-20062478
Medical News Today. (2023, June 20). Wellbutrin drug interactions: What to know. https://www.medicalnewstoday.com/articles/drugs-wellbutrin-interactions
